Lilly Moves Into Migraine Race With CHMP Okay
Executive Summary
Competition is hotting up in the CGRP class of new migraine therapies, with Lilly's Emgality being recommended for approval in Europe, paving the way for a market share battle with Novartis' Aimovig.
You may also be interested in...
Novartis Gets NICE Headache From Aimovig Knockback
The cost-effectiveness watchdog is worried about the cost of Novartis's once-monthly first-in-class migraine drug and is not convinced it is more effective than Allergan’s Botox, which can require up to 40 injections into the head and neck.
Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.
Lilly Looks To Emgality Access, Injector And Data To Differentiate Its CGRP Inhibitor
The three US FDA-approved anti-CGRP antibodies for migraine prevention have similar efficacy and matching prices, but Lilly thinks access to Emgality – including through value-based arrangements – along with the biologic's ease of use and headache-free data will differentiate the product.